Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Research & Development (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Research & Development data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Research & Development rose 54.88% year-over-year to $2.6 million; the TTM value through Oct 2025 reached $8.4 million, up 13.57%, while the annual FY2025 figure was $6.8 million, 28.49% down from the prior year.
  • Research & Development reached $2.6 million in Q4 2025 per CSBR's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $3.2 million in Q1 2023 and bottomed at $1.5 million in Q3 2024.
  • Average Research & Development over 5 years is $2.3 million, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Research & Development: tumbled 47.94% in 2024, then soared 54.88% in 2025.
  • A 5-year view of Research & Development shows it stood at $2.3 million in 2021, then grew by 13.27% to $2.6 million in 2022, then fell by 3.42% to $2.5 million in 2023, then plummeted by 32.84% to $1.7 million in 2024, then skyrocketed by 54.88% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $2.6 million in Q4 2025, $2.1 million in Q3 2025, and $2.0 million in Q2 2025.